Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues. The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe.
Ro partners with Eli Lilly to offer Zepbound, an FDA-approved obesity treatment, at affordable cash-pay prices through an integrated platform with home delivery.
According to the announcement, the share repurchase program allows for flexibility in purchasing methods, including open market and privately negotiated transactions.
Jefferies downgrades Biogen with a reduced price target, citing pipeline setbacks, slow Leqembi sales, and challenges from declining Ocrevus royalties.
The company lowered its FY2024 guidance following Q3 earnings, citing supply chain challenges for top-selling drugs like Mounjaro and Zepbound and a one-time R&D expense from its $3.2 billion acquisition of Morphic Holdings.
Eli Lilly plans a $3 billion expansion of its Wisconsin facility, creating 750 skilled jobs and boosting production capacity for critical medicines with advanced automation.
Results for Amgen's weight loss drug Maritide were highly anticipated, but fell short. However, MariTide could still turn the tables in future studies.
